BRST5:Inflammatory myofibroblastic tumour: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
Kgeiersbach (talk | contribs) |
||
| Line 81: | Line 81: | ||
|Yes (ALK-negative IMTs may have a higher likelihood of metastasis) | |Yes (ALK-negative IMTs may have a higher likelihood of metastasis) | ||
|Yes | |Yes | ||
|IMT with ALK genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" /> | |IMT with ''ALK'' genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" /> | ||
|- | |- | ||
|t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3) | |t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3) | ||
| Line 99: | Line 99: | ||
|No | |No | ||
|Yes | |Yes | ||
|Therapy options for NTRK fusions include | |Therapy options for ''NTRK'' fusions include larotrectinib and entrectinib (clinically approved) | ||
|- | |- | ||
|t(5;12)(q32;q13.3) | |t(5;12)(q32;q13.3) | ||
|NAB2::PDGFRB | |''NAB2''::''PDGFRB'' | ||
|der(5) | |der(5) | ||
|>1%<ref name=":8" /> | |>1%<ref name=":8" /> | ||
| Line 111: | Line 111: | ||
|- | |- | ||
|rea(10q11.21) | |rea(10q11.21) | ||
|rea(RET) | |rea(''RET'') | ||
|der(10) | |der(10) | ||
|>1%<ref name=":5" /> | |>1%<ref name=":5" /> | ||
| Line 240: | Line 240: | ||
==References== | ==References== | ||
<references /> | |||
<br /> | <br /> | ||